UK service level audit of insulin pump therapy in paediatrics

A Ghatak1, P Paul1, D B Hawcutt1,2

  • 1Alder Hey Children's Hospital, Liverpool, UK.

Insights

This audit of UK insulin pump therapy found that while the number of children using continuous subcutaneous insulin infusion aligns with NICE guidelines, there

Area of Science:

  • Pediatric Endocrinology
  • Diabetes Technology
  • Healthcare Policy

Background:

  • NICE guidelines (Technology Appraisal 151) were issued in 2008 for continuous subcutaneous insulin infusion (CSII) therapy.
  • Insulin pump therapy is a key treatment for Type 1 diabetes in children and young people.
  • Auditing CSII provision is crucial for assessing guideline adherence and service delivery.

Purpose of the Study:

  • To audit the provision of insulin pump therapy (CSII) for children and young people in the UK.
  • To assess alignment with NICE Technology Appraisal 151 guidelines.
  • To identify challenges and gaps in pediatric CSII services.

Main Methods:

  • An online audit of all UK centers providing pump services to pediatric patients.
  • Metrics aligned with NICE Technology Appraisal 151.
  • Data collected using an electronic tool.

Main Results:

  • 94.3% of identified UK centers participated, covering 5094 pediatric patients on CSII (19% of pediatric Type 1 diabetes patients).
  • Significant lack of formally funded healthcare professional time (consultant, diabetes specialist nurse, dietitian) for pump services.
  • Gaps identified in structured education programs (only 53% of units) and written inpatient guidelines (only 56% of units).
  • 9% of units reported funding refusals for patients meeting NICE criteria.

Conclusions:

  • Pediatric CSII use in the UK is consistent with NICE estimates.
  • A critical shortage of funded healthcare professional time dedicated to CSII services exists.
  • Deficiencies in structured patient education and standardized inpatient guidelines require urgent attention.
Abstract

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.3K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
360
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
1.2K
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
886
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
391
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
838